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Abstract: In vitro and in vivo clinical and experimental data have suggested that leukotrienes 
play a key role in inﬂ  ammatory reactions of the skin. Antileukotriene drugs, ie, leukotriene receptor 
antagonists and synthesis inhibitors, are a class of anti-inﬂ  ammatory drugs that have shown 
clinical efﬁ  cacy in the management of asthma and in rhinitis with asthma. We searched 
MEDLINE database and carried out a manual search on journals specializing in allergy and 
dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective 
in chronic urticaria associated with aspirin (ASA) or food additive hypersensitivity or with 
autoreactivity to intradermal serum injection (ASST) when taken with an antihistamine but 
not in mild or moderate chronic idiopathic urticaria [urticaria without any possible secondary 
causes (ie, food additive or ASA and other NSAID hypersensitivity, or ASST)]. Evidence for 
the effectiveness of zaﬁ  rlukast and the 5-lipoxygenase inhibitor, zileuton, in chronic urticaria 
is mainly anecdotal. In addition, there is anecdotal evidence of effectiveness of antileukotrienes 
in primary cold urticaria, delayed pressure urticaria and dermographism. No evidence exists 
for other physical urticarias, including cholinergic, solar and aquagenic urticarias, vibratory 
angioedema, and exercise-induced anaphylaxis.
Keywords: chronic idiopathic urticaria, leukotriene receptor antagonists, montelukast, 
zaﬁ  rlukast, antihistamine
Urticaria is a common disorder of the skin, affecting between one in four and one in six 
people, sometimes throughout their lives. Urticarial episodes of up to 6 weeks’ dura-
tion are classiﬁ  ed as acute, whereas those lasting longer are considered chronic. The 
clinical characteristic of chronic urticaria (CU) are repeated occurrences of short-lived 
cutaneous wheals accompanied by redness and itching exceeding 6 weeks. The indi-
vidual wheals last less than 24 hours, with the exceptions of delayed pressure urticaria 
and urticarial vasculitis, which persist for 24 to 72 hours. Wheals are lesions ranging 
from a few millimeters to several centimeters in diameter. The itch of urticaria is the 
hallmark symptom, and it is usually worse in the evening or nighttime. CU typically 
follows this diurnal pattern. Angioedema (AE) accompanies 40% to 50% of the cases 
of chronic urticaria and 10% of the patients experience only AE without hives.1–3 In 
these patients the treatments have focused on symptom control.
Pathogenesis of urticaria
The weal or hive is the “ﬁ  nal pathway” involving dermal mast-cells. This pathway 
is activated by various trigger factors through immunological or nonimmunological 
mechanisms and the result is the release of preformed (eg, histamine) and newly 
synthesized mediators (eg, arachidonic acid metabolites), with potent effects on the 
micro-vasculature.2Journal of Asthma and Allergy 2009:2 10
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The most popular theory to explain the development of 
CU is referred to as the autoimmune hypothesis. This notion 
had its origins in 1924, when Lewis and Grant improved 
the technique of experimentally creating histamine wheals 
initially described by Eppinger in 1913.4
The suggestion that chronic idiopathic urticaria (CIU) 
may have an autoimmune basis came from the recognition 
that thyroid auto-antibodies and thyroid dysfunction were 
observed more commonly in patients with CIU.4
The suggestion that a serologic factor is responsible 
for the pathogenesis of CIU has been a dominant theme in 
the literature for more than 20 years. In 1986, a serologic 
mediator called HRF was identiﬁ  ed in patients with CU 
using an in vivo skin test called the autologous serum skin 
test (ASST).5
We demonstrated that both aspirin (ASA) and food addi-
tives determine a signiﬁ  cant increase in urinary leukotriene 
4 (LTE4) levels, after oral speciﬁ  c challenge in patients with 
CU and hypersensitivity to ASA or food additives. The 
urinary LTE4 levels were compared between patients with CU 
and hypersensitivity to ASA or food additives, patients with 
CU but tolerating both ASA and food additives, and healthy 
subjects. No difference was found at baseline between the 
three groups. After a speciﬁ  c challenge with ASA and food 
additives, the urinary excretion levels of LTE4 were signiﬁ  -
cantly higher in patients affected by CU and hypersensitivity 
to ASA or food additives than in patients with CU but without 
hypersensitivity to ASA or food additives and in healthy 
subjects.6,7
Therapy of urticaria
The management of CU remains a challenge for both clini-
cians and patients. Primary recommendations for the man-
agement of CU include general measures such as avoidance 
of any aggravating stimuli, topical antipruritic emollients, 
reassurance and education, and speciﬁ  c pharmacotherapy, of 
which the newer selective H1-antihistamines are the preferred 
intervention.1 However, the prior generation “sedating” 
antihistamines remain useful, efﬁ  cacious ﬁ  rst-line agents 
for many patients.
Some of these nonselective antihistamines have other 
useful receptor properties that may extend additional efﬁ  cacy 
in certain cases. Such agents include doxepin, cyprohepta-
dine, and ketotifen.8–10 The H2-antihistamines are also used 
in clinical practice, most often as add-on therapy, but these 
agents generally offer modest incremental efﬁ  cacy.11 In 
addition to combining multiple antihistamines in such a way, 
higher doses of antihistamines are widely recommended or 
prescribed;12 however, the evidence supporting this practice 
is minimal.13
Oral corticosteroids almost always control urticaria and 
are undoubtedly the most versatile and useful second-line 
therapy. However, the incidence of side-effects is substantial 
if the dose, the duration of use, or both, are too great.14 Other 
second-line therapies include sulphasalazine15 and thyroxine.16 
While third-line, immunosuppressive therapies for severe CU 
are now accepted practice, there is still the problem of know-
ing which patients have autoimmune urticaria and are there-
fore most likely to respond, even if there is some evidence 
for the therapeutic effect of immunosuppression therapy in 
patients without autoimmune urticaria.17 Newer biologic and 
nonbiologic immunomodulatory agents, approved for other 
indications and in clinical development, provide potential 
options for this often severe CU.18
Urticaria treatment 
with antileukotrienes
The efficacy and, primarily, safety of the leukotriene 
modiﬁ  ers have placed these agents at the top of the list of 
alternative agents, and future practice may place them along-
side antihistamines as ﬁ  rst-line therapy.19
We searched MEDLINE database and carried out a 
manual search on journals specializing in allergy and 
dermatology for the use of antileukotriene drugs in urticaria. 
Even though treatment with antileukotrienes in urticaria has 
not been recommended by manufacturers of the drugs, we 
found numerous anecdotal and open-series reports and some 
placebo-controlled studies on the treatment of urticaria with 
cysteinyl-leukotriene antagonists. The studies were evaluated 
using the parameters of Shekelle (Tables 1, 2).20
Rationale of the treatment 
with antileukotrienes
Injected leukotriene D4 is more potent than histamine in 
causing a wheal and ﬂ  are.21 Serum from patients with CIU 
with positive ASST or negative ASST, since patients cannot 
have both idiopathic and autoimmune disease, is capable 
of releasing leukotrienes, in addition to other mediators.22 
Leukotriene-mediated urtication is not blocked by other 
agents.23
Anecdotal series and open studies
Anecdotal studies suggested therapeutic effects for antileu-
kotrienes in the treatment of urticaria exacerbations induced 
by ASA24 and other nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs) in patients with CIU,25 chronic autoimmune Journal of Asthma and Allergy 2009:2 11
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urticaria,26 acquired cold urticaria,27,28 delayed-pressure 
urticaria (DPU),29 and intractable CIU.30 A single negative 
study reported a pranlukast-evoked urticaria in patients 
affected by ASA-induced urticaria.31 However, this molecule 
is not marketed in Europe and in US (Table 3).
Other open studies, with more patients, suggested a ben-
eﬁ  cial effect for antileukotrienes in the treatment of DPU,32 
steroid-dependent urticaria33,34 chronic idiopathic urticaria,35,36 
and dermographism.35 Patients with allergic urticaria showed 
less beneﬁ  t.35 Nettis et al treated patients affected by chronic 
idiopathic urticaria with montelukast or fexofenadine. They 
demonstrated that montelukast had a better therapeutic effects 
compared with fexofenadine. The majority of the patients pre-
sented a positive ASST and, after therapy with montelukast, 
were unreactive to autologous serum.37
A case report suggested a beneﬁ  cial effect for antileukot-
rienes in the treatment of urticaria exacerbation induced by a 
COX-2 selective inhibitors.38 Another study demonstrated in 
22/25 patients the effect of antileukotrienes in the treatment 
of urticaria exacerbation induced by ASA or NSAIDs.39 
Finally, a comparison between montelukast and cetirizine 
demonstrated that cetirizine is better than montelukast in 
monotherapy.40
Controlled studies
A double-blind, placebo-controlled study demonstrated a 
better therapeutic effect of montelukast vs cetirizine and 
placebo in patients with ASA and ⁄or food additive-induced 
urticaria.41
Perez et al demonstrated that in individuals with histories 
of recurrent episodes of urticaria and⁄or angioedema after the 
administration of different NSAIDs, pretreatment with mon-
telukast before a single-blind oral challenge with NSAIDs, 
completely or partially prevented the reaction in most of those 
patients.42 In a double-blind, placebo-controlled trial compar-
ing cetirizine plus zaﬁ  rlukast vs cetirizine plus placebo in 
patients affected by CU refractory to H1-antagonist mono-
therapy, Bagenstose et al demonstrated that only patients 
with autoreactive (positive ASST) CU might beneﬁ  t from 
the addition of the leukotriene receptor antagonist zaﬁ  rlukast 
to their treatment regimen.43
A randomized, single-blind, placebo-controlled, cross-
over study with montelukast vs placebo, using a nonsedating 
H1-antihistamine when needed, demonstrated that monte-
lukast might be an effective and safe therapeutic agent in 
the treatment of patients with refractory chronic idiopathic 
urticaria, including patients with intolerance to NSAIDs and 
positivity to ASST.44
Reimers et al in a double-blind, placebo-controlled, 
crossover study, treated with zaﬁ  rlukast a heterogeneous 
population of patients with CU. In comparison with placebo, 
treatment with zaﬁ  rlukast resulted in no signiﬁ  cant positive 
effect for any of the efﬁ  cacy measures, but it may be relevant 
that a high proportion of patients had dermographism.45
Nettis et al reported on another randomized, double-
blind, placebo-controlled study conducted on patients 
with a diagnosis of mild CU, randomized to receive once 
daily: (a) oral desloratadine plus placebo; (b) desloratadine 
plus montelukast; or (c) oral placebo alone. In this study, 
the combination of desloratadine plus montelukast was 
effective in the treatment of CU.46 Di Lorenzo et al treated 
160 patients affected by chronic idiopathic urticaria with 
montelukast alone or in combination with a nonsedating 
antihistamine (desloratadine), or only with nonsedating 
antihistamine, or with matched placebo. In this study, we 
evaluated only patients affected by moderate chronic idio-
pathic urticaria.
This is an important difference compared with some of the 
previous reports, in which patients were selected without pre-
cise characteristics.33,34,46 In patients with moderate chronic 
idiopathic urticaria, the role of leukotrienes is probably 
rather insigniﬁ  cant.6,43 In this study, montelukast alone 
Table 1 Categories of evidence
Categories of evidence
Ia Meta-analysis of randomized controlled 
trials (RTC)
Ib At least one RTC
IIa At least one controlled study without 
randomization
IIb At least one other type of study
III Non-experimental descriptive studies
IV Expert committee reports or opinions 
or clinical experience of respected 
authorities
Table 2 Strength of evidence
Strength of evidence
A Category I evidence
B Category II evidence or 
extrapolated recommendation 
from category I evidence
C Category III evidence or 
extrapolated recommendation 
from category I or II evidence
D Category IV evidence or 
extrapolated recommendation 
from category I or II or III evidenceJournal of Asthma and Allergy 2009:2 12
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was less effective than the combination with nonsedating 
antihistamine and appeared not to be useful in controlling 
the symptoms of urticaria compared with nonsedating 
antihistamine alone. Therefore, the expected synergistic inter-
action between antileukotrienes and antihistamines was not 
conﬁ  rmed in mild chronic idiopathic urticaria.47 This result is 
in accordance with another noncontrolled study40 (Table 4). 
Conclusions
Leukotriene receptor antagonists are currently the best-
studied group of drugs after the antihistamines, in the therapy 
of CU. However, the leukotriene receptor antagonists aren’t 
alternative agents to antihistamines. The excellent safety, 
absence of required monitoring in the case of montelukast and 
zaﬁ  rlukast, and wide availability make leukotriene receptor 
antagonists the preferred supplementary agents to try with 
antihistamines. Although one study suggested persistent 
drug-free remission,44 most experience argues against such 
a disease-modifying effect. Leukotriene receptor antagonists 
appear to be useful as both monotherapy and add-on therapy 
but are not likely to displace antihistamines from their role 
as ﬁ  rst-line therapy.
In our review, leukotriene receptor antagonists may 
provide improvement in patients with food additive 
hypersensitivity or ASA and other NSAID-exacerbated 
CIU24,25,31,38,39,41,42 and in patients with positive ASST 
results.26,37,44 In other words, in the type of chronic urticaria 
without any associated cause, very idiopathic urticaria, the 
use of leukotriene receptor antagonists demonstrates lack of 
advantage if administered both in monotherapy and com-
bined with antihistamines.
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